Menu
1 min read · estimated
APPROVED USE
What FDA approved
To lower relapse risk in adults and children with high-risk neuroblastoma who achieved at least a partial response after multiagent, multimodality treatment that included anti-GD2 immunotherapy.
LAMPGEN ANALYSIS
Why it matters
The approved use targets relapse risk after a response to intensive treatment.
What research teams should watch
Document prior anti-GD2 exposure and best response when assessing eligibility.
PRIMARY RECORDS